Latest Conference

The results were shared in a poster presentation at the 2024 APSARD Annual Meeting.

Ann Childress, MD, the current president of APSARD, invites you to attend this year's conference!

In an exclusive interview, APSARD President Elect Greg Mattingly, MD, tells Psychiatric Times readers what they can expect at this year's meeting.

Did you miss the 2023 Annual Psychiatric Times World CME Conference? Don't worry, we've got you covered.

Updates from Day 2 at the National Academy of Sciences Conference on adult ADHD.

Check out these updates for the National Academy of Sciences Conference on adult ADHD, including new research, thoughtful discussions, and more!

These important findings on esketamine nasal spray as a treatment for young individuals with suicidal ideation were presented at the ACNP 2023 Annual Meeting. We interviewed the vice president and head of neuropsychiatry clinical development at Johnson & Johnson Innovative Medicine to learn more.

What neuromodulation can be used to specifically target nicotine users with schizophrenia? This research may tell us.

ECT: a gold-standard treatment for major depressive disorder. Ketamine/esketamine: a newer therapeutic option. This ACNP 2023 Annual Meeting session took a deeper look.

Deep brain stimulation for substance use disorders when everything else fails, the history of the ACNP, and more.

Research presented at the ACNP 2023 Annual Meeting shows that neuromodulation therapy cTBS could be a viable schizophrenia-specific intervention for nicotine use.

Exciting research ideas are stirring at the ACNP 2023 Annual Meeting.

Neurosteroid therapeutics could be the solution to provide fast-acting treatment for mothers with postpartum depression.

Check out these brief summaries on cognitive impairment in schizophrenia from an excellent session at the ACNP 2023 Annual Meeting!

DBS in psychiatry: What challenges stand between this treatment and success? Alik Widge, MD, PhD, shares more at the ACNP 2023 Annual meeting.

Did you catch the President's Plenary at the ACNP 2023 Annual Meeting?

Navacaprant—a novel, oral, once-daily, highly selective kappa opioid receptor antagonist that is currently in phase 3 development as a monotherapy for major depressive disorder.

Don't miss this ACNP 2023 Annual Meeting session!

Michael F. Myers, MD provided tips and advice to clinicians who might be dealing with a patient contemplating suicide.

“Epidemiological surveys have shown that gender gaps and alcohol consumption and alcohol-related harms are narrowing for women and men—such that alcohol is growing women’s health issue.”

Tony Thrasher, DO, DFAPA, shared his thoughts on emergency psychiatry: an honor and a great stressor.

What are some key considerations in diagnosing bipolar disorder? Joseph F. Goldberg, MD, shares insights at the recent 2023 Annual Psychiatric Times World CME Conference.

An expert addresses some common concerns about the drug and some effective ways clinicians can initiate the treatment at the 2023 Annual Psychiatric Times™ World CME Conference.

What are the treatment options for insomnia when avoiding benzodiazepines? John W. Winkelman MD, PhD, shares insights and guidance at the 2023 Annual Psychiatric Times World CME Conference.

Here’s why you should initiate clozapine sooner in patients with treatment-resistant schizophrenia.

An expert discusses motivational interviewing at the 2023 Annual Psychiatric Times™ World CME Conference.

Sanjai Rao, MD, shared best practices for utilizing long-acting injectable antipsychotics at the 2023 Psychiatric Times World CME Conference.

Don't miss the the 2023 Psychiatric Times World CME conference, where our Editor in Chief will present on the 14 different types of dementia!